HALOZYME THERAPEUTICS
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and di... spersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptinรยฎ, MabTheraรยฎ, immunoglobulin, Cinryzeรยฎ and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need.
HALOZYME THERAPEUTICS
Industry:
Biotechnology Marketing Medical
Founded:
1998-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.halozyme.com
Total Employee:
101+
Status:
Active
Contact:
858.794.8889
Email Addresses:
[email protected]
Total Funding:
245 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager WordPress Wordpress Plugins Organization Schema IPv6 ReCAPTCHA Cloudflare JS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Dice Therapeutics
Dice Therapeutics develops a transformative platform designed for the discovery of novel small molecules.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2022-04-13 | Antares Pharma | Antares Pharma acquired by Halozyme Therapeutics | 960 M USD |
Investors List
Janssen Biotech
Janssen Biotech investment in Post-IPO Equity - Halozyme Therapeutics
arGEN-X
arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Halozyme Therapeutics
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Halozyme Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Halozyme Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-02-02 | Halozyme Appoints New Chief Financial Officer |
2020-02-24 | Halozyme Announces CFO Transition |
Official Site Inspections
http://www.halozyme.com Semrush global rank: 3.28 M Semrush visits lastest month: 5 K
- Host name: 104-237-144-180.ip.linodeusercontent.com
- IP address: 104.237.144.180
- Location: Newark United States
- Latitude: 40.739
- Longitude: -74.1697
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07175